The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer
Open accessAbstract
In human cancers, loss of PTEN, stabilization of hypoxia inducible factor-1α, and activation of Ras and AKT converge to increase the activity of a key regulator of glycolysis, 6-phosphofructo-2-kinase (PFKFB3). This enzyme synthesizes fructose 2,6-bisphosphate (F26BP), which is an activator of 6-phosphofructo-1-kinase, a key step of glycolysis. Previously, a weak competitive inhibitor of PFKFB3, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), was found to reduce the glucose metabolism and proliferation of cancer cells. We have synthesized 73 derivatives of 3PO and screened each compound for activity against recombinant PFKFB3. One small molecule, 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15), was selected for further preclinical evaluation of its pharmacokinetic, antimetabolic, and antineoplastic properties in vitro and in vivo. We found that PFK15 causes a rapid induction of apoptosis in transformed cells, has adequate pharmacokinetic properties, suppresses the glucose uptake and growth of Lewis lung carcinomas in syngeneic mice, and yields antitumor effects in three human xenograft models of cancer in athymic mice that are comparable to U.S. Food and Drug Administration–approved chemotherapeutic agents. As a result of this study, a synthetic derivative and formulation of PFK15 has undergone investigational new drug (IND)-enabling toxicology and safety studies. A phase I clinical trial of its efficacy in advanced cancer patients will initiate in 2013 and we anticipate that this new class of antimetabolic agents will yield acceptable therapeutic indices and prove to be synergistic with agents that disrupt neoplastic signaling. Mol Cancer Ther; 12(8); 1461–70. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation
Wang, R., Dillon, C. P., Shi, L. Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L. L., Fitzgerald, P., Chi, H., Munger, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.021 · Cited by 2,140 · cited 1×
“Given our growing understanding of the immunosuppressive effects of regulatory T cells (25) andmyeloid-derived suppressor cells (26) and the differential metabolic requirements of various T-cell subsets (27), we speculate that PFKFB3 inhibitors may have unidentified pleiotropic effects on the immune system that may co…”
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
c-Myc transactivation of LDH-A : Implications for tumor metabolism and growth
Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., & Dang, C. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6658 · Cited by 1,092
MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities
Dang, C. V., Le, A., & Gao, P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0889 · Cited by 946
Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc
Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D., Lee, L. A., & Dang, C. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000023200 · Cited by 879
Herrero-Mendez, A., Almeida, A., Fernández, E., Maestre, C., Moncada, S., & Bolaños, J. P. (2009) · Nature Cell Biology · doi:10.1038/ncb1881 · Cited by 844
Clem, B., Telang, S., Clem, A., Yalcin, A., Meier, J., Simmons, A., Rasku, M. A., Arumugam, S., Dean, W. L., Eaton, J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0482 · Cited by 432
Self-citationRegulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer
Yalcin, A., Telang, S., Clem, B., & Chesney, J. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.003 · Cited by 405
Self-citationMarsin, A.-S., Bouzin, C., Bertrand, L., & Hue, L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205213200 · Cited by 379
Systemic elevation of PTEN induces a tumor-suppressive metabolic state
Garcia-Cao, I., Song, M. S., Hobbs, R. M., Laurent, G., Giorgi, C., de Boer, V. C. J., Anastasiou, D., Ito, K., Sasaki, A. T., Rameh, L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.030 · Cited by 377
Cited by
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349
Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?
Hay, N. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.77 · Cited by 1,115
Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression
Li, Z., & Zhang, H. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2070-4 · Cited by 830
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
Metadata
- Authors
- Clem, B. F., O'Neal, J., Tapolsky, G., Clem, A. L., Imbert-Fernandez, Y., Kerr, D. A., Klarer, A. C., Redman, R., Miller, D. M., Trent, J. O., Telang, S., & Chesney, J.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2013-08-01
- Volume
- 12
- Issue
- 8
- Pages
- 1461-1470
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2095985189
- Cited by
- 276
- References
- 26
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-13-0097
- The paper
- Clem, B. F., O'Neal, J., Tapolsky, G., Clem, A. L., Imbert-Fernandez, Y., Kerr, D. A., Klarer, A. C., Redman, R., Miller, D. M., Trent, J. O., Telang, S., & Chesney, J. (2013). Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-13-0097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.